메뉴 건너뛰기




Volumn 75, Issue 10, 2004, Pages 1374-1375

Intravenous immunoglobulins: A treatment for Alzheimer's disease?

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; AMYLOID BETA PROTEIN ANTIBODY; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; CLUSTERIN; FC RECEPTOR; IMMUNOGLOBULIN; PROTEIN ANTIBODY; SERUM AMYLOID P; UNCLASSIFIED DRUG;

EID: 4644337032     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.2004.043141     Document Type: Editorial
Times cited : (9)

References (6)
  • 1
    • 11544279355 scopus 로고    scopus 로고
    • Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins
    • Lambert MP, Barlow AK, Chromy BA, et al. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A 1998;95:6448-53.
    • (1998) Proc Natl Acad Sci U S A , vol.95 , pp. 6448-6453
    • Lambert, M.P.1    Barlow, A.K.2    Chromy, B.A.3
  • 2
    • 0033536163 scopus 로고    scopus 로고
    • Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse
    • Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999;400:173-7.
    • (1999) Nature , vol.400 , pp. 173-177
    • Schenk, D.1    Barbour, R.2    Dunn, W.3
  • 3
    • 0033835996 scopus 로고    scopus 로고
    • Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease
    • Bard F, Cannon C, Barbour R, et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000;6:916-9.
    • (2000) Nat Med , vol.6 , pp. 916-919
    • Bard, F.1    Cannon, C.2    Barbour, R.3
  • 4
    • 4644275963 scopus 로고    scopus 로고
    • Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease
    • Dodel R, Du Y, Depboylu C, et al. Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease. J Neurol Neurosurg Psychiatry 2004;75:1472-4.
    • (2004) J Neurol Neurosurg Psychiatry , vol.75 , pp. 1472-1474
    • Dodel, R.1    Du, Y.2    Depboylu, C.3
  • 5
    • 0030892121 scopus 로고    scopus 로고
    • Intravenous immune globulin therapy for neurologic diseases
    • Dalakas MC. Intravenous immune globulin therapy for neurologic diseases. Ann Intern Med 1997;126:721-30.
    • (1997) Ann Intern Med , vol.126 , pp. 721-730
    • Dalakas, M.C.1
  • 6
    • 0034161462 scopus 로고    scopus 로고
    • Vasoactive side effects of intravenous immunoglobulin preparations in a rat model and their treatment with recombinant platelet-activating factor acetylhydrolase
    • Bleeker WK, Teeling JL, Verhoeven AJ, et al. Vasoactive side effects of intravenous immunoglobulin preparations in a rat model and their treatment with recombinant platelet-activating factor acetylhydrolase. Blood 2000;95:1856-61.
    • (2000) Blood , vol.95 , pp. 1856-1861
    • Bleeker, W.K.1    Teeling, J.L.2    Verhoeven, A.J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.